EXAS — Exact Sciences Income Statement
0.000.00%
Last trade - 00:00
- $12.11bn
- $13.75bn
- $2.50bn
- 65
- 31
- 47
- 45
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 876 | 1,491 | 1,767 | 2,084 | 2,500 |
Cost of Revenue | |||||
Gross Profit | 660 | 1,137 | 1,308 | 1,510 | 1,846 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,110 | 2,259 | 2,623 | 2,678 | 2,704 |
Operating Profit | -234 | -768 | -856 | -594 | -205 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -406 | -829 | -843 | -633 | -202 |
Provision for Income Taxes | |||||
Net Income After Taxes | -213 | -824 | -596 | -624 | -204 |
Net Income Before Extraordinary Items | |||||
Net Income | -213 | -824 | -596 | -624 | -204 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -213 | -824 | -596 | -624 | -204 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.62 | -2.77 | -3.08 | -3.48 | -1.17 |